BioCryst Pharmaceuticals (BCRX)
|
1.43
-0.08 (-5.30%)
|
|
|
|
BCRX additional information
Market Data powered by QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Filings and Fundamentals by Morningstar, Insiders by Vickers (USA) and SEDI(CDN), analyst ratings by Zacks.
BCRX Profile
•
Exchange
NASDAQ
•
Held by these Mutual Funds
DFA US Micro Cap I
T. Rowe Price Health Sciences
iShares Nasdaq Biotechnology
Vanguard Extended Market Idx
iShares Russell 2000 Growth Index
JPMorgan Small Cap Core Select
DFA US Small Cap I
CREF Stock
Rydex Biotechnology Adv
Vanguard Instl Ttl Stk Mkt Idx InstlPlus
T. Rowe Price Health Sciences
iShares Nasdaq Biotechnology
Vanguard Extended Market Idx
iShares Russell 2000 Growth Index
JPMorgan Small Cap Core Select
DFA US Small Cap I
CREF Stock
Rydex Biotechnology Adv
Vanguard Instl Ttl Stk Mkt Idx InstlPlus
•
Executives
Mr. Jon P. Stonehouse
Chief Exec. Officer
Pres and Exec. Director
Mr. Thomas R. Staab II A
44
Chief Financial Officer Sr. VP and Treasurer
Dr. William P. Sheridan MBBS
Chief Medical Officer and Sr. VP
Mr. David S. McCullough
VP of Strategic Planning
Commercialization & Corp. Devel.
Dr. Yarlagadda S. Babu Ph.D.
VP of Drug Discovery
Chief Exec. Officer
Pres and Exec. Director
Mr. Thomas R. Staab II A
44
Chief Financial Officer Sr. VP and Treasurer
Dr. William P. Sheridan MBBS
Chief Medical Officer and Sr. VP
Mr. David S. McCullough
VP of Strategic Planning
Commercialization & Corp. Devel.
Dr. Yarlagadda S. Babu Ph.D.
VP of Drug Discovery
•
Employee Count
75
Special Offers
Competitors
BCRX earnings
Date
Actual
Expected
Prev Yr Qtr
2/16/2012
-0.29
-0.29
-0.20
8/4/2011
-0.34
-0.27
-0.23
2/10/2011
-0.20
-0.21
0.35
